E. Warlick

发表

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

L. Weiner, Jeffrey S. Miller, J. Ross, 2014, Blood.

MYELOID NEOPLASIA CD 16 xCD 33 bispeci fi c killer cell engager ( BiKE ) activates NK cells against primary MDS and MDSC CD 33 1 targets

L. Weiner, Jeffrey S. Miller, J. Ross, 2014 .

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

J. Wagner, M. Kirstein, D. Weisdorf, 2016, Translational research : the journal of laboratory and clinical medicine.

Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia.

D. Weisdorf, B. Oran, Q. Cao, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)

B. Hirsch, P. Nguyen, J. Poynter, 2021, Cancer Causes & Control.

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

H. Kantarjian, Jeffrey S. Miller, A. Frankel, 2015, Clinical Cancer Research.

Phase I Study of a Bispeci fi c Ligand-Directed Toxin Targeting CD 22 and CD 19 ( DT 2219 ) for Refractory B-cell Malignancies

H. Kantarjian, Jeffrey S. Miller, A. Frankel, 2015 .

Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation

D. Steensma, Bryce Waldman, A. Brunner, 2021, Cancer.

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.

D. Kaufman, J. Wagner, K. Dusenbery, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplant Recipients.

S. Bhatia, D. Weisdorf, M. Arora, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Jeffrey S. Miller, S. Spellman, D. Weisdorf, 2018, Blood advances.

Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach

S. Yohe, C. Ustun, E. Warlick, 2017, BMC Clinical Pathology.

Cord Blood Transplants for Myeloid Malignancies in Adults

E. Warlick, 2017 .

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

M. Aljurf, R. Gale, K. Ballen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndromes Patients ≥70 Years Old

M. Arora, N. Bejanyan, T. DeFor, 2016 .

Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years.

D. Weisdorf, M. Arora, N. Bejanyan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Alan M. Miller, R. Vij, W. Wood, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

J. Ross, B. Hirsch, P. Nguyen, 2015, Cancer epidemiology.

Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population‐based study

J. Cerhan, B. Hirsch, P. Nguyen, 2017, International journal of cancer.

Matching at HLA-C improved the outcomes after double umbilical cord blood transplantation for recipients of 2–4/6 HLA-matched grafts

J. Wagner, K. Ballen, R. Soiffer, 2017 .

Surveillance imaging after autologous hematopoietic cell transplantation predicts survival in patients with diffuse large B cell lymphoma.

D. Weisdorf, V. Bachanova, Z. Cayci, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.

P. Nguyen, J. Poynter, A. Linabery, 2022, Cancer epidemiology.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings.

J. Wagner, Jeffrey S. Miller, M. MacMillan, 2021, Blood advances.

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation

D. Weisdorf, B. Blazar, M. Verneris, 2014 .

The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study

P. Nguyen, J. Poynter, M. Richardson, 2021, Leukemia & lymphoma.

Alcohol use is not a significant contributor to myelodysplastic syndromes

P. Nguyen, J. Poynter, A. Cioc, 2020, Cancer Causes & Control.

Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation

J. Wagner, G. Vercellotti, M. Verneris, 2014, Bone Marrow Transplantation.

Epidemiology of myelodysplastic syndromes: many questions remain

E. Warlick, 2011, Leukemia & lymphoma.

Clofarabine desensitization: A case report

S. M. Hayes, E. Warlick, Justin A Wasko, 2017, Leukemia research reports.

decitabine vorinostat and haploidentical natural killer cell infusions with il 2 atimulation in high risk myelodysplastic syndrome

M. Patnaik, J. Miller, D. McKenna, 2018 .

Transplantation provides superior survival high risk myeloid malignancies in older patients

C. Ustun, L. Burns, E. Warlick, 2022, Leukemia & lymphoma.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

Jeffrey S. Miller, Q. Cao, E. Warlick, 2013, Leukemia.

Prognostic factors for clinical outcomes of patients with central nervous system leukemia

D. Weisdorf, V. Bachanova, N. Bejanyan, 2020, Hematology/oncology and stem cell therapy.

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

E. Warlick, S. McCormack, 2010, OncoTargets and therapy.

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

H. Kohrt, R. Vij, M. Aljurf, 2012, Blood.

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

M. Linden, M. Burke, J. Miller, 2013, Bone Marrow Transplantation.

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Bin Zhang, Jeffrey S. Miller, J. Ross, 2013, Clinical Cancer Research.

Absence of early HHV‐6 reactivation after cord blood allograft predicts powerful graft‐versus‐tumor effect

Jeffrey S. Miller, D. Weisdorf, A. Rashidi, 2018, American journal of hematology.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Alan M. Miller, R. Vij, M. Aljurf, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study

Jeffrey S. Miller, J. Ross, B. Hirsch, 2012 .

The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries

M. Horowitz, D. Weisdorf, J. D. Rizzo, 2012 .

Effect of Keratinocyte Growth Factor on Hospital Readmission and Regimen-Related Toxicities after Autologous Hematopoietic Cell Transplantation for Lymphoma.

D. Weisdorf, M. Arora, A. Rashidi, 2021, Transplantation and cellular therapy.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.

J. Wagner, D. Weisdorf, M. Arora, 2019, Blood advances.

Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)

B. Hirsch, J. Poynter, A. Cioc, 2021, Cancer Causes & Control.

Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients.

D. Weisdorf, B. Oran, C. Brunstein, 2009 .

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

Zhe Zhang, S. Piantadosi, J. Kowalski, 2011, Leukemia research.

Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients

S. Bhatia, D. Weisdorf, M. Arora, 2022, Bone Marrow Transplantation.

Hematopoietic Cell Transplant Related Toxicities and Mortality in Frail Recipients.

S. Bhatia, D. Weisdorf, M. Arora, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

J. Wagner, Jeffrey S. Miller, D. Weisdorf, 2018, Blood advances.

Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.

M. Robin, D. Weisdorf, G. Socié, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.

Alan M. Miller, R. Vij, F. Baron, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

M. Linden, M. Burke, J. Miller, 2013, Bone Marrow Transplantation.

Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.

D. Weisdorf, B. Oran, Q. Cao, 2011, Leukemia research.

Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions

E. Warlick, 2010, Current opinion in oncology.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

D. Weisdorf, T. DeFor, A. Cioc, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.

C. Huff, M. Borowitz, Richard J. Jones, 2008, Leukemia research.

Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.

B. Smith, E. Warlick, 2007, Current cancer drug targets.

Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.

D. Weisdorf, M. Arora, A. Rashidi, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients

C. Thoburn, B. Smith, Y. Kasamon, 2018, Leukemia & lymphoma.

Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

J. Kowalski, Richard J. Jones, B. Smith, 2016, Leukemia research.

Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms.

J. Wagner, M. Sanz, J. Sanz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

M. Zahurak, Richard J. Jones, B. Smith, 2021, Leukemia research.

R. Porcher, M. Robin, P. Chevallier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Higher Therapeutic Cyclosporine Levels Early Post-Transplantation Reduces Risks of Acute Graft-Versus-Host Disease and Improves Survival

D. Weisdorf, B. Blazar, M. Arora, 2013, Bone Marrow Transplantation.

Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics

Jeffrey S. Miller, M. MacMillan, D. Weisdorf, 2018, Haematologica.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

J. Wagner, K. Ballen, R. Soiffer, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML

J. Wagner, D. Weisdorf, T. DeFor, 2014, Bone Marrow Transplantation.

Myelodysplastic syndromes: the role of the immune system in pathogenesis

Jeffrey S. Miller, Jeffrey S Miller, E. Warlick, 2011, Leukemia & lymphoma.

Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies.

M. Arora, V. Bachanova, Q. Cao, 2021, Transplantation and cellular therapy.

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.

M. Linden, D. Weisdorf, N. Bejanyan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

J. Wagner, D. Weisdorf, N. Majhail, 2012, Bone Marrow Transplantation.

Myelodysplastic Syndromes: Pathophysiology

S. Gore, E. Warlick, 2011 .

Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population‐based study

B. Hirsch, P. Nguyen, J. Poynter, 2019, European journal of haematology.

Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.

Jeffrey S. Miller, D. Weisdorf, B. Blazar, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation

M. Linden, A. Rashidi, J. Miller, 2018, Bone Marrow Transplantation.

Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD

J. Wagner, D. Weisdorf, M. Verneris, 2016, Haematologica.

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

S. Bhatia, G. Vercellotti, M. MacMillan, 2021, Blood Cancer Journal.

Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.

K. Dusenbery, G. Vercellotti, Jeffrey S. Miller, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.

Jeffrey S. Miller, B. Blazar, M. Verneris, 2020, JCI insight.

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Jeffrey S. Miller, D. Weisdorf, D. Vallera, 2020 .

Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.

D. Weisdorf, T. DeFor, Z. Sachs, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease‐negative first complete remission

M. Linden, D. Weisdorf, A. Rashidi, 2017, American journal of hematology.

Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant

J. Wagner, M. MacMillan, D. Weisdorf, 2021, Bone Marrow Transplantation.

R. Porcher, M. Robin, P. Chevallier, 2012 .

Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.

J. Cerhan, J. Ross, B. Hirsch, 2016, Cancer epidemiology.

Association between mitochondrial DNA haplogroup and myelodysplastic syndromes

A. J. Hooten, J. Ross, B. Hirsch, 2015, Genes, chromosomes & cancer.

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD

Jeffrey S. Miller, M. MacMillan, D. Weisdorf, 2016, Bone Marrow Transplantation.

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival

M. Reding, D. Weisdorf, M. Reding, 2015, Bone Marrow Transplantation.

Myeloablative vs. reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: a systematic review and meta-analysis.

H. Chu, M. Pasquini, S. Devine, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prophylactic foscarnet for human herpesvirus 6: effect on hematopoietic engraftment after reduced intensity conditioning umbilical cord blood transplantation.

J. Wagner, D. Weisdorf, M. Arora, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

P. Greenberg, M. Horowitz, B. Logan, 2019, JAMA oncology.

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

D. Weisdorf, A. Rashidi, N. Bejanyan, 2018, Leukemia & lymphoma.

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes

N. Bejanyan, C. Ustun, C. Brunstein, 2016, Bone Marrow Transplantation.

Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome

D. Weisdorf, T. DeFor, Z. Sachs, 2016, Bone Marrow Transplantation.

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor.

J. Wagner, Chi Chen, G. Vercellotti, 2020, Blood advances.

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: Comparable Outcomes With Unrelated Umbilical Cord Blood and HLA-Identical Sibling Donors

J. Wagner, D. Weisdorf, N. Majhail, 2011 .